Inquiry Basket
Loading ......
Macrophage migration inhibitory factor (MIF) is a cytokine involved in the regulation of innate and adaptive immune responses. Over the years, extensive studies have revealed that MIF expression is significantly increased in a variety of tumor tissues, promoting tumor growth, metastasis, and angiogenesis, and inducing the formation of the tumor microenvironment (TME). In view of the important promoting role of MIF in the occurrence and development of tumors, targeting MIF is considered a potential strategy for treating cancer.
MIF is a protein that forms a trimer structure. The trimer is composed of three identical subunits, each consisting of two antiparallel alpha helices and a four-stranded beta-sheet. This arrangement creates a central channel within the trimer, which exhibits 3-fold rotational symmetry. MIF is constitutively expressed in various cell types, including macrophages, T lymphocytes, and epithelial cells.
Fig. 1 Three-dimensional structural homology of MIF. (Calandra T, et al., 2003)
One of the key functions of MIF is its role in the regulation of the immune system. It acts as a pro-inflammatory cytokine, promoting the secretion of other cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). MIF also stimulates the recruitment and activation of immune cells, including macrophages, neutrophils, and T lymphocytes, further amplifying the inflammatory response.
Recent studies have found that the expression level of MIF in solid tumor tissues such as breast cancer, prostate cancer, and pancreatic cancer is significantly higher than that in normal tissues, and the expression level is significantly related to the metastasis and invasion ability of tumors. On the one hand, MIF is directly involved in the regulation of tumor cells; on the other hand, it is indirectly involved in the development of tumor-related diseases through the inflammatory response, immune response, and TME.
As a multifunctional cytokine, MIF mainly interacts with the membrane receptor CXC family (such as CXCR2, CXCR4, CXCR7, CXCR12), CD74, and CD44 to activate downstream signaling pathways and exert biological functions. Among them, MIF can regulate the activity of CD74 and cause homeostasis disorders such as inflammation, tumors, and autoimmune diseases. In addition, MIF binds to the chemokines CXCR2 and CXCR4, recruits leukocytes, and accelerates the process of atherosclerosis. Studies have found that these membrane receptors usually bind to MIF in the form of complexes (such as CXCR4/CD74, CXCR2/CD74, CD74/CD44) to regulate cell functions. For example, MIF binds to the CD74/CD44 complex to activate Syk, Akt, NF-κB, and other signals to regulate immune responses.
MIF also exerts biological functions in the cytoplasm. Intracellular MIF regulates cellular functions through protein-protein interactions. For example, MIF interacts with the serine protease HTRA1 to inhibit the hydrolytic activity of HTRA1 protein, affecting cell growth and differentiation ability, and MIF interacts with the apoptosis-related protein BNIPL to participate in the apoptosis process.
Given the involvement of MIF in numerous disease pathways, there is considerable interest in developing therapeutic strategies that modulate MIF activity. Several approaches are being explored, including reducing MIF enzyme activity, reducing MIF protein amount, and anti-MIF antibodies.
Current drugs targeting MIF are mainly small molecule inhibitors targeting its enzymatic activity. Most of these inhibitors were discovered through computer-aided drug design (CADD) and virtual screening (VS) technology. There are at least 11 types of small-molecule inhibitors that have been discovered so far. Their main mechanisms of action are:
Reducing intracellular MIF expression by destroying MIF stability and promoting its degradation, or inhibiting MIF transcription, is also a strategy for targeting MIF drugs. For example, studies have found that NADPH oxidase 4 can upregulate MIF mRNA and protein levels. Therefore, research targeting NADPH oxidase 4 may be able to find new inhibitors for MIF expression and provide new ideas for drug research targeting MIF.
Monoclonal antibodies targeting MIF such as BaxG03, BaxB01, and BaxM159 inhibit MAPK/ERK1/2 activity by targeting MIF, reducing the proliferation and invasion ability of prostate cancer cell PC3, and significantly inhibiting tumor growth. For example, in the CT26 colon cancer model, neutralizing antibodies against MIF have shown good tumor inhibition effects.
Creative Diagnostics, with a commitment to innovation and scientific excellence, is at the forefront of MIF research. By providing reliable MIF ELISA kits and anti-MIF antibodies and contributing to the development of MIF-targeted therapies, Creative Diagnostics is empowering researchers and clinicians to advance our understanding and treatment of diseases influenced by MIF.
References
Loading ......
